Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-044366
Filing Date
2025-03-25
Accepted
2025-03-25 16:07:46
Documents
77
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K antx-20241231.htm   iXBRL 10-K 2717681
2 EX-10.17 antx-ex10_17.htm EX-10.17 44253
3 EX-10.18 antx-ex10_18.htm EX-10.18 276092
4 EX-19.1 antx-ex19_1.htm EX-19.1 134141
5 EX-23.1 antx-ex23_1.htm EX-23.1 3481
6 EX-31.1 antx-ex31_1.htm EX-31.1 15962
7 EX-31.2 antx-ex31_2.htm EX-31.2 15717
8 EX-32.1 antx-ex32_1.htm EX-32.1 9281
9 EX-32.2 antx-ex32_2.htm EX-32.2 9273
10 GRAPHIC img92015643_0.jpg GRAPHIC 123178
  Complete submission text file 0000950170-25-044366.txt   10696094

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20241231.xsd EX-101.SCH 1320744
80 EXTRACTED XBRL INSTANCE DOCUMENT antx-20241231_htm.xml XML 1595495
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41331 | Film No.: 25768334
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)